Akums Drugs & Pharmaceuticals, a New Delhi-based contract development and manufacturing organisation (CDMO), has announced the launch of Rabeprazole + Levosulpiride SR capsules. Approved by the Drug Controller General of India (DCGI), this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD.

Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology.

Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals said, “It's crucial to raise awareness about GERD to mitigate the risk of developing this condition. The introduction of Rabeprazole + Levosulpiride SR Capsules shows Akums' commitment to providing effective pharmaceutical solutions that cater to medical needs."